|  |
| --- |
| **SUPPLEMENTARY MATERIAL**Restrictive spirometry pattern is associated with low physical activity levels. *A population based international study* |

Anne-Elie Carsin, Elaine Fuertes, Emmanuel Schaffner, Debbie Jarvis, Josep M Antó, Joachim Heinrich, Valeria Bellisario, Cecilie Svanes, Dirk Keidel, Medea Imboden, Joost Weyler, Dennis Nowak, Jesus Martinez-Moratalla, José-Antonio Gullón, José Luis Sanchez Ramos, Seraina Caviezel, Anna Beckmeyer-Borowko, Chantal Raherison, Isabelle Pin, Pascal Demoly, Isa Cerveri, Simone Accordini, Thorarinn Gislason, Kjell Toren, Bertil Forsberg, Christer Janson, Rain Jogi, Margareta Emtner, Francisco Gómez Real, Wasif Raza, Bénédicte Leynaert, Silvia Pascual , Stefano Guerra, Shyamali Dharmage, Nicole Probst-Hensch, Judith Garcia-Aymerich

* **Table S1.** Odds Ratio (OR) and 95% confidence interval of all variables included in the models for low physical activity in ECRHS and SAPALDIA
* **Figure S1.** Odds ratios (OR) for low physical activity in restrictive spirometry pattern compared to normal spirometry pattern (reference group) using logistic regression stratified by sex, BMI and smoking status. Meta-analysed estimates from ECRHS and SAPALDIA
* **Figure S2.** Sensitivity analyses. Odds ratios (OR) for low physical activity in restrictive spirometry pattern compared to normal spirometry pattern (reference group) using logistic regression, in ECRHS (dashed line), SAPALDIA (dotted line) and meta-analysed (solid line)
* **Local Principal Investigators, senior scientific teams and funding agencies for the European Community Respiratory Health Survey**

**Table S1.** Odds Ratio (OR) and 95% confidence interval of all variables included in the models for low physical activity in ECRHS and SAPALDIA

|  |  |  |  |
| --- | --- | --- | --- |
|   |   | **Low physical activity 1** | **Low physical activity 2** |
|   |   | <1st tertile of total MET·min/week | <2 times/week or <1h/week |
|   |  | ECRHS | SAPALDIA | ECRHS | SAPALDIA |
|  |  | OR 95%CI | OR 95%CI | OR 95%CI | OR 95%CI |
| Normal spirometry |  | 1 | 1 | 1 | 1 |
| Restrictive spirometry pattern | 1.44 (1.03-2.02) | 1.35 (0.83-2.19) | 1.43 (1.01-2.01) | 1.28 (0.79-2.09) |
| Age |  | 0.98 (0.89-1.07) | 0.86 (0.76-0.96) | 1.21 (1.12-1.32) | 1.22 (1.10-1.35) |
| Sex | male | 1 | 1 | 1 | 1 |
|  | female | 1.18 (0.99-1.40) | 1.08 (0.88-1.33) | 1.30 (1.11-1.53) | 1.38 (1.14-1.67) |
| BMI  |  | 1.03 (1.01-1.05) | 1.02 (0.99-1.04) | 1.03 (1.01-1.04) | 1.01 (0.99-1.04) |
| Education level | low | - | 1 | 1 | 1  |
|   | mid | - | 0.70 (0.42-1.16) | 0.79 (0.57-1.10) | 0.68 (0.38-1.19) |
|   | high | - | 1.08 (0.64-1.81) | 0.80 (0.58-1.11) | 0.58 (0.32-1.04) |
| Smoking | never | - | 1 | 1 |  1 |
|   | ex | - | 1.10 (0.89-1.36) | 0.80 (0.67-0.95) | 0.92 (0.76-1.12) |
|   | current | - | 1.13 (0.84-1.53) | 1.55 (1.22-1.97) | 1.57 (1.18-2.09) |
| Physically active 10-year before | 0.50 (0.41-0.59) | 0.58 (0.47-0.72) | 0.33 (0.28-0.39) | 0.28 (0.23-0.33) |
| Depression |  | 1.23 (0.98-1.55) | NA | 1.22 (0.97-1.52) | NA |
| Diabetes |  | 1.19 (0.80-1.78) | - | 1.23 (0.84-1.81) |  - |
| Heart disease |  | 1.13 (0.64-2.01) | NA | - | NA  |
| Hypertension |  | 1.14 (0.91-1.43) | 1.24 (0.98-1.58) | - | -  |
| Stroke |  | 2.80 (1.16-6.73) | 1.38 (0.63-3.03) | - | 4.62 (1.36-15.69) |

OR: Odds Ratio. 95%CI: 95% Confidence Interval. NA: not available in this study.

Lowest study-specific tertile: ECRHS: <1390. SAPALDIA: <2550 MET·min/week.

**Figure S1.** Odds ratios (OR) for low physical activity in restrictive spirometry pattern compared to normal spirometry pattern (reference group) using logistic regression stratified by sex, BMI and smoking status. Meta-analysed estimates from ECRHS and SAPALDIA



**Low physical**

**activity 2**

**Low physical**

**activity 1**

**Low physical**

**activity 2**

**Low physical**

**activity 1**

**Low physical**

**activity 2**

**Low physical**

**activity 1**

Lowest study-specific tertile: ECRHS: <1390, SAPALDIA: <2550 MET·min/week. Combined estimates (meta-analysed OR) for low physical activity comparing subjects with restrictive spirometry pattern to subjects with normal spirometry, adjusted for same confounders as in main model (figure 2, table S1).

**Figure S2.** Sensitivity analyses. Odds ratios (OR) for low physical activity in restrictive spirometry pattern compared to normal spirometry pattern (reference group) using logistic regression, in ECRHS (dashed line), SAPALDIA (dotted line) and meta-analysed (solid line)



**Low physical activity 2 (<2 times/week or <1 h/week)**

**Low physical activity 1 (<1st tertile of total MET·min/week)**

Lowest study-specific tertile: ECRHS: <1390, SAPALDIA: <2550. GLI eq: GLI-equations were used instead of study-specific equations to define spirometry patterns. Fixed cut: fixed cut-off <2000 MET·min/week. Excl. asthma: excluding asthmatics. Excl. res symp: excluding subjects with respiratory symptoms. Adj %fat mass: adjusted for % fat mass (ECRHS only). Pre-BD: using lung function from pre-bronchodilator. IPW cor: estimates were corrected for loss of follow-up using inverse probability weights (ECRHS only) All estimates adjusted for same confounders as in main model (figure 2, table S1).

**Local Principal Investigators, senior scientific teams and funding agencies for the European Community Respiratory Health Survey**

***ECRHS*** *III* ***Principal Investigators and senior scientific teams***

**Belgium: South Antwerp & Antwerp City** (J. Weyler, H.Bentouhami, V. Nelen ); **Estonia:** Tartu (R. Jõgi, H.Orru); **France: Bordeaux** (C. Raherison, P.O Girodet), **Grenoble** (I. Pin, V. Siroux, J.Ferran, J.L Cracowski), **Montpellier** (P. Demoly,A.Bourdin, I. Vachier), **Paris** (B. Leynaert, D. Soussan, D. Courbon, C. Neukirch, L. Alavoine, X. Duval, I. Poirier); **Germany: Erfurt** (J .Heinrich, E. Becker, G. Woelke, O. Manuwald), **Hamburg** (H. Magnussen, D. Nowak, A-M Kirsten); **Iceland: Reykjavik** (T. Gislason, B. Benediktsdottir, D. Gislason, E.S Arnardottir, M. Clausen, G. Gudmundsson, L. Gudmundsdottir, H. Palsdottir, K. Olafsdottir, S. Sigmundsdottir, K. Bara-Jörundsdottir); **Italy**: **Pavia** (I .Cerveri, A.Corsico, A. Grosso, F. Albicini, E. Gini, E.M Di Vincenzo, V. Ronzoni, S. Villani, F. Campanella, M. Gnesi, F. Manzoni, L. Rossi, O. Ferraro), **Turin:** (M. Bugiani, R. Bono, P. Piccioni, R. Tassinari, V. Bellisario, G. Trucco), **Verona:** (R de Marco†, S. Accordini, L. Calciano, L. Cazzoletti, M. Ferrari, A.M Fratta Pasini, F. Locatelli, P. Marchetti, A. Marcon, E. Montoli, G. Nguyen, M. Olivieri, C. Papadopoulou, C.Posenato, G. Pesce, P. Vallerio, G. Verlato, E. Zanolin); **Norway:** (C. Svanes, E. Omenaas, A. Johannessen, T. Skorge, F. Gomez Real); **Spain:** **Albacete** (J. Martinez-Moratalla Rovira, E. Almar, A. Mateos, S. García, A. Núñez, P.López, R. Sánchez, E Mancebo), **Barcelona:** (J-M. Antó, J.P Zock, J Garcia-Aymerich, M Kogevinas, X. Basagaña, A.E. Carsin, F. Burgos, C. Sanjuas, S Guerra, B. Jacquemin, P.Davdand, **Galdakao**: (N. Muñozguren, I. Urrutia, U. Aguirre, S. Pascual), **Huelva**: (J Antonio Maldonado, A. Pereira, J. Luis Sánchez, L. Palacios), **Oviedo**: (F. Payo, I. Huerta, N. Sánchez, M. Fernández, B. Robles); **Sweden: Göteborg** (K. Torén, M. Holm, J-L Kim, A-C. Olin, A. Dahlman-Höglund), **Umea** (B. Forsberg, L. Braback, L Modig, B Järvholm, H Bertilsson, K.A Franklin, C Wahlgreen), **Uppsala:**(B Andersson, D Norback, U Spetz Nystrom, G Wieslander, G.M Bodinaa Lund, K Nisser); **Switzerland:** **Basel** (N.M. Probst-Hensch, N. Künzli, D. Stolz, C. Schindler, T. Rochat, J.M. Gaspoz, E. Zemp Stutz, M.Adam, C. Autenrieth, I. Curjuric, J. Dratva, A. Di Pasquale, R. Ducret-Stich, E. Fischer, L. Grize, A. Hensel, D. Keidel, A. Kumar, M. Imboden, N. Maire, A. Mehta, H. Phuleria, M. Ragettli, M. Ritter, E. Schaffner, G.A Thun, A. Ineichen, T. Schikowski, M. Tarantino, M. Tsai); **United Kingdom: London** (P. Burney, D. Jarvis, S. Kapur, R. Newson, J. Potts,), **Ipswich:** (N. Innes), **Norwich**: (A. Wilson).

***Financial Support for ECRHS*** *III*

**Belgium: Antwerp South, Antwerp City:** Research Foundation Flanders(FWO), grant code G.0.410.08.N.10 (both sites); **Estonia: Tartu-** SF0180060s09 from the Estonian Ministry of Education; **France:** (**All**) Ministère de la Santé. Programme Hospitalier de Recherche Clinique (PHRC) national 2010, **Bordeaux:** INSERM U897 Université Bordeaux segalen, **Grenoble:** Comite Scientifique AGIRadom 2011, **Paris:** Agence Nationale de la Santé, Région Ile de France, domaine d’intérêt majeur (DIM); **Germany: Erfurt:** German Research Foundation HE 3294/10-1, **Hamburg**: German Research Foundation MA 711/6-1, NO 262/7-1; **Iceland:** **Reykjavik**: The Landspitali University Hospital Research Fund, University of Iceland Research Fund, ResMed Foundation, California, USA, Orkuveita Reykjavikur (Geothermal plant), Vegagerðin (The Icelandic Road Administration (ICERA); **Italy:** All Italian centres were funded by the Italian Ministry of Health, Chiesi Farmaceutici SpA, in addition **Verona** was funded by Cariverona foundation, Education Ministry (MIUR). **Norway:** Norwegian Research council grant no 214123, Western Norway Regional Health Authorities grant no 911631, Bergen Medical Research Foundation; **Spain:** Fondo de Investigación Sanitaria (PS09/02457, PS09/00716 09/01511) PS09/02185 PS09/03190), Servicio Andaluz de Salud , Sociedad Española de Neumología y Cirurgía Torácica (SEPAR 1001/2010), **Barcelona:** Fondo de Investigación Sanitaria (FIS PS09/00716), **Galdakao:** Fondo de Investigación Sanitaria (FIS 09/01511), **Huelva**: Fondo de Investigación Sanitaria (FIS PS09/02185) and Servicio Andaluz de Salud, **Oviedo:** Fondo de Investigación Sanitaria (FIS PS09/03190) ; **Sweden:** All centres were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association, The Swedish Association against Lung and Heart Disease, Swedish Research Council for health, working life and welfare (FORTE), **Göteborg:** also received further funding from the Swedish Council for Working life and Social Research, **Umea:** also received funding from Vasterbotten Country Council ALF grant; **Switzerland:** The Swiss National Science Foundation (grants no 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099) The Federal office for forest, environment and landscape, The Federal Office of Public Health, The Federal Office of Roads and Transport, the canton’s government of Aargan, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais and Zürich, the Swiss Lung League, the canton's Lung League of Basel Stadt/ Basel, Landschaft, Geneva, Ticino, Valais and Zurich, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA, **United Kingdom:** Medical Research Council (Grant Number 92091). Support also provided by the National Institute for Health Research through the Primary Care Research Network.